Drug makers around the world are racing to develop the first effective COVID-19 vaccine. Early efforts show promise, but an anticipated jump in the novel coronavirus cases in the fall means the sooner a vaccine is developed, the more lives can be saved-and the pharmaceutical industry plays a major role in this discovery.
Fast Healthcare Interoperability Resources, or FHIR, is a long-awaited interoperability rule that will enable seamless, on-demand information exchange of clinical records among providers and data systems and will result in coordinated, cost-efficient care.
Utilization and revenue were half of March and April 2019 levels for oral surgery, cardiology, dermatology, gastroenterology, and orthopedics.
Three new scientific theories explaining that although autoimmune disease affects both genders, women are at an overwhelming disadvantage.
COVID-19 is "laying bare the lethal inequality" of American society and health care, says Adam Gaffney, M.D., the lead author of a study about COVID-19 risk and insurance coverage.
The COVID-19 pandemic is having a dramatic impact on healthcare, the global economy, and people’s daily lives. FinTech executive Monica Eaton-Cardone notes that the crisis also underscores the need to encourage women to make careers in science, technology, engineering, and math.
Cancer researchers at Children's Hospital of Philadelphia (CHOP) are repurposing tools used for the development of cancer immunotherapies to identify regions of the SARS-CoV-2 virus to target with a vaccine, employing the same approach used to elicit an immune response against cancer cells to stimulate an immune response against the virus.
Website, media campaign designed to encourage Philadelphians who need help to seek it.
Five pharma markers are recalling the diabetes medication due to the presence of a carcinogenic ingredient.
HHS says supply could run out by the end of this month.
As the U.S. begins reopening, potentially sparking a “second wave” of COVID-19 cases, hospitals and health systems will need to continue operating in a state of high-stress readiness.
Nothing can bring a healthcare system to its knees quite like a pandemic. What COVID-19 is leaving in its wake is a new respect for numbers - for accurate data that can predict new threats, track current ones and trigger an avalanche of innovative responses.
During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech presented plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials.
The agency welcomes another option for serious bacterial infections.
Survey of over 1,000 people shows that use of telehealth has tripled.
As COVID-19 has spread around the world, data has shown that those with weakened immune systems are among the most susceptible to severe illness from the virus.
Amid considerable uncertainty in healthcare, quality care coordination is largely within your own control and can make an immensely positive impact on those you serve.
Dwindling reliance on primary care physicians is burdening healthcare system and limiting care resources.
The Institute for Clinical and Economic Review (ICER) found siponimod has benefits for patients with active secondary progressive multiple sclerosis, but its benefits were in line with other therapies in a crowded marketplace.
Much remains unknown about how precisely multiple sclerosis occurs and advances in patients, but a growing body of research is helping scientists develop new ways to slow, and potentially stop, disease progression.
Proving therapeutic equivalence is a major hurdle.
Developing a biosimilar can be more challenging than developing the innovator product because of the need to match the attributes of a highly complex molecules.
Hotspots can be predicted by identifying areas with a large percentage of residents with chronic conditions.
For those of us who spend our lives and careers fighting to improve care for individuals with the most significant medical, social and behavioral health needs, a study that found disappointing results from a well-regarded model will not deter us, but only reinforce the power and necessity of our endeavor.
Kathi Mooney, Ph.D., RN, FAAN, interim senior director of population sciences at the Huntsman Cancer Institute in Salt Lake City, discusses hospital-at-home programs and how they are common in countries with single-payer systems and include patients with conditions ranging from cellulitis to heart failure. The benefits include the familiarity of home surroundings, avoidance of hospital-acquired infection, and less de-conditioning from being in a hospital bed.
Anesthesia practices see major financial hit as physician anesthesiologists pivot during COVID-19 to treat patients in critical care and ICUs, ASA survey highlights.
Brilinta is already approved to prevent atherothrombotic events in ASC.
Immediately after the FDA said it found elevated levels of the carcinogenic ingredient N-nitrosodimethylamine (NDMA) in certain extended release (ER) metformin products, the first 2 major recalls are underway.
